Neuropace INC Form 4 insider transactions

NeuroPace's Chief Medical Officer, Martha Morrell, had 3,051 shares withheld by the company to cover tax obligations related to a restricted stock unit vesting.

NeuroPace Director Uri Geiger reported the acquisition of 1,194 shares of common stock at $9.94 per share, issued as part of his non-employee director compensation.

NeuroPace Director Joseph Lacob acquired 1,131 shares of common stock at $9.94 per share as part of his compensation, increasing his beneficial ownership.

NeuroPace Inc. Director Rakhi Kumar acquired 1,509 shares of common stock at $9.94 per share as part of her compensation.

NeuroPace Director Frank Fischer acquired 2,389 shares of common stock as part of his compensation, increasing his total beneficial ownership to 591,920 shares.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, disposed of 1,337 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

NeuroPace Inc.'s CEO, Joel Becker, disposed of 1,126 shares of common stock on August 27, 2025, to cover tax withholding obligations related to a restricted stock unit award.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, disposed of 357 shares of common stock at $8.88 per share to cover tax withholdings from a restricted stock unit award vesting.

NeuroPace Chief Medical Officer Martha Morrell disposed of 3,052 shares of common stock to cover tax withholding obligations related to a restricted stock unit award vesting.

NeuroPace Inc. Director Rakhi Kumar has increased her direct beneficial ownership of common stock through a series of acquisitions as part of the company's non-employee director compensation policy.

NeuroPace Inc.'s Chief Financial Officer, Patrick F. Williams, was granted 51,850 restricted stock units and options to purchase 87,950 shares of common stock, aligning his interests with shareholders.

NeuroPace Inc. Director Uri Geiger has significantly increased his direct beneficial ownership of company common stock through a series of acquisitions as part of his non-employee director compensation policy.

NeuroPace Inc. Director Joseph Lacob has reported a series of stock acquisitions totaling 11,696 shares between June 2023 and June 2025, issued as compensation for his board service.

NeuroPace Inc. Director Frank M. Fischer has consistently increased his direct beneficial ownership of common stock by a total of 23,874 shares across nine transactions from June 2023 to June 2025, primarily through issuances as part of his non-employee director compensation.

NeuroPace Inc. Director Renee Ryan was granted 8,745 stock options with an exercise price of $13.15 per share, vesting over 12 months.

NeuroPace Inc. Director Joseph Lacob was granted 8,745 stock options with an exercise price of $13.15, vesting monthly over one year.

NeuroPace Inc. Director Rakhi Kumar was granted 8,745 stock options with an exercise price of $13.15, vesting monthly over one year, as disclosed in a recent SEC Form 4 filing.

NeuroPace Inc. Director R Scott Huennekens was granted 8,745 stock options with an exercise price of $13.15, vesting over 12 months, as disclosed in a recent SEC Form 4 filing.

NeuroPace Inc. Director Uri Geiger has acquired 8,745 stock options with an exercise price of $13.15, vesting over 12 months.

NeuroPace Inc. Director Frank M. Fischer was granted 8,745 stock options with an exercise price of $13.15, vesting over 12 months.

NeuroPace Inc. Director Lisa Andrade was granted 8,745 stock options with an exercise price of $13.15, as disclosed in a recent SEC Form 4 filing.

NeuroPace Inc.'s Chief Financial Officer, Rebecca Kuhn, reported the disposition of 1,337 shares of common stock on June 3, 2025, at a price of $13.54 per share, primarily to cover tax withholding obligations.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported the disposition of 1,338 shares of common stock to cover tax withholding obligations related to equity vesting.

NeuroPace Inc. CEO and Director Joel Becker reported the disposition of 1,126 shares of common stock at $12.66 per share on May 27, 2025, primarily to cover tax obligations.

NeuroPace Inc.'s Chief Financial Officer, Rebecca Kuhn, reported the disposition of 357 shares of common stock on May 27, 2025, at a price of $12.66 per share, primarily to cover tax withholding obligations.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, reported the disposition of 357 shares of common stock at $12.66 per share to cover tax withholding obligations.

Rebecca Kuhn, CFO of NeuroPace Inc, reports disposing of 3,051 shares of common stock to cover tax obligations.

Martha Morrell, Chief Medical Officer of NeuroPace Inc., reports disposing of 3,051 shares of common stock to cover tax obligations.

OrbiMed Advisors LLC, a major shareholder of NeuroPace Inc, reports selling a portion of its common stock holdings.

Rebecca Kuhn, CFO of NeuroPace Inc, reported the disposal of 237 shares of common stock to cover tax obligations.